Background. Macrolide resistance among group A Streptococcus (GAS) is common in many countries. We analyzed prevalence of resistance to erythromycin (EryR) and other antibiotics among GAS isolates obtained from CDC's Active Bacterial Core surveillance (ABCs) over a 14-year period.
Methods. ABCs is active, laboratory-and population-based surveillance for select bacterial infections in 10 geographically diverse U.S. sites. Isolates from invasive GAS infections were collected in participating ABCs sites from 1999-2012. Susceptibility was assessed using broth microdilution and D-zone testing for inducible clindamycin resistance (CliR); emm typing was performed using DNA sequencing.
Results. We tested 9175 (85%) isolates from 10,794 invasive GAS cases; 10.5% were EryR. Both EryR and CliR increased over the 14 years (test for trend: 10 (emm 12, 49, 58, 73, 75, 76, 83, 92, 94, 114) accounted for 21% of all isolates but 65% of EryR isolates. Site-specific variability in EryR prevalence was primarily due to fluctuations of these emm types. Among 105 EryR isolates from 2012, 62 (59%) were inducibly CliR and 35 (41%) constitutively CliR; 72 of CliR (74.2%) were also tetracycline-resistant. Data from 2001-2010 indicated that a genetic element that contains both ermTR and tetM accounted for most CliR. The patient case fatality ratio did not differ by EryR (10.7% EryR vs 12.2% erythromycin susceptible; P = 0.18). EryR infections were more common (P < 0.05) among men than women (11.7% vs 9.3%) and among persons age 18-34 (13.2%) and 50-64 years (13.1%) than other age groups. EryR was lowest among children age <5 years (7.5%).
Conclusion. Macrolide resistance among invasive GAS infections in the U.S. gradually increased over 14 years. However, local frequency of macrolide-resistant GAS infections fluctuated markedly, depending on circulating strains. Community-specific susceptibility testing is important for clinical management. Penicillin remains a good choice for therapy of invasive GAS infections.
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